Allist (688578.SH): Marketing application for new indication of furmonertinib mesylate tablets accepted

Zhito Finance APP News, Allist (688578.SH) announced that recently, the company received the "Notice of Acceptance" approved and issued by the National Medical Products Administration. The company's marketing application for furmonertinib mesylate tablets (referred to as "furmonertinib") for a new indication of adjuvant treatment after tumor resection in adult patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations has been accepted.